CanSino Biologics Inc (CJH) — Capital Reinvestment Ratio
Latest as of December 2021:
0.35x
CanSino Biologics Inc (CJH) has a Capital Reinvestment Ratio of 0.35x as of December 2021, meaning it reinvests 0% of its operating cash flow (€806.73 Million) in capital expenditures (€284.07 Million). See how much free cash does CanSino Biologics Inc generate to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.35x
Capex / Operating Cash Flow
Operating Cash Flow
€806.73 Million
EUR
Capital Expenditures
€284.07 Million
EUR
Data as of
Dec 2021
Most recent filing
CanSino Biologics Inc Capital Reinvestment Ratio (2021–2025)
This chart tracks CanSino Biologics Inc's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for CanSino Biologics Inc (2021–2025)
Year-by-year Capital Reinvestment Ratio for CanSino Biologics Inc from 2021 to 2025. For live market cap and broader valuation context, see CJH company net worth.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 3.13x | €77.86 Million | €243.90 Million | ▲ +433.8% |
| 2021 | 0.59x | €2.05 Billion | €1.20 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow